Chen Wei, Sun Xin, Wang Wen-jian, Fu Xiao-dong, Fu De-yu, Zhou Jing-min, Wu Yi-ling
Department of Emergency, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Zhonghua Yi Xue Za Zhi. 2008 Aug 19;88(32):2271-3.
To investigate the effects of tongxinluo (TXL) capsule on cardiac ventricle remodeling after acute myocardial infarction (AMI).
Seventy AMI patients were randomly divided into 2 equal groups: conventional therapy group treated with conventional Western therapy and TXL treatment group treated with TXL capsule for 6 weeks in addition to the conventional treatment. Cardiac color ultrasound was conducted before and 6 weeks after the treatment to examine the changes of ventricular structure, mass and function. Radioimmunoassay was used to detect the levels of angiotensin II (Ang II) and endothelin-1 (ET-1).
Six weeks later, the left ventricular posterior wall thickness of end-diastolic (LVPWTD), left ventricular end-systolic dimension (LVESD), and left atrium dimension (LAD) of the TXL group were 0.93 cm +/- 0.09 cm, 3.71 cm +/- 0.19 cm, and 3.21 cm +/- 0.29 cm respectively, all lower than those before treatment (0.93 cm +/- 0.09 cm, 3.71 cm +/- 0.19 cm, and 3.21 cm +/- 0.29 cm respectively) and those of the conventional treatment group (0.95 cm +/- 0.08 cm, 3.62 cm +/- 0.46 cm, and 3.82 cm +/- 0.30 cm) (all P < 0.05), the ejection-fraction (EF) improvement rate of the TXL group was 63% +/- 7%, significantly higher than that before treatment (52% +/- 6%) and that of the conventional treatment group (59% +/- 8%, both P < 0.05).
TXL capsule in addition to conventional therapy has a positive effect on the prognosis of AMI via reversing the ventricular remodeling, and improving cardiac function.
探讨通心络（TXL）胶囊对急性心肌梗死（AMI）后心室重构的影响。
70例AMI患者随机分为两组，每组35例。常规治疗组采用常规西医治疗，通心络治疗组在常规治疗基础上加用通心络胶囊治疗6周。治疗前及治疗6周后行心脏彩色超声检查，观察心室结构、质量及功能变化。采用放射免疫法检测血管紧张素Ⅱ（AngⅡ）和内皮素-1（ET-1）水平。
治疗6周后，通心络组左心室舒张末期后壁厚度（LVPWTD）、左心室收缩末期内径（LVESD）和左心房内径（LAD）分别为（0.93±0.09）cm、（3.71±0.19）cm和（3.21±0.29）cm，均低于治疗前（分别为0.93±0.09）cm、（3.71±0.19）cm和（3.21±0.29）cm）及常规治疗组（0.95±0.08）cm、（3.62±0.46）cm和（3.82±0.30）cm）（均P<0.05）；通心络组射血分数（EF）改善率为（63±7）%，明显高于治疗前（52±6）%及常规治疗组（59±8）%（均P<0.05）。
通心络胶囊联合常规治疗可通过逆转心室重构、改善心功能，对AMI预后产生积极影响。
